Roble, Belko & Company, Inc Bristol Myers Squibb CO Transaction History

Roble, Belko & Company, Inc

$634 Million
Q3 2024

A detailed history of Roble, Belko & Company, Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Roble, Belko & Company, Inc holds 100 shares of BMY stock, worth $5,319. This represents 0.0% of its overall portfolio holdings.

Number of Shares

100

Previous 100 -0.0%

Holding current value

$5,319

Previous $4,000 25.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$65.71 - $74.53 $10,513 - $11,924	-160 Reduced 61.54%	100 $7,000
Q2 2022 Aug 10, 2022	SELL	$72.62 - $79.98 $18,155 - $19,995	-250 Reduced 49.02%	260 $20,000
Q1 2022 May 06, 2022	BUY	$61.48 - $73.72 $15,370 - $18,430	250 Added 96.15%	510 $37,000
Q3 2021 Nov 03, 2021	SELL	$59.17 - $69.31 $59 - $69	-1 Reduced 0.38%	260 $15,000
Q3 2020 Nov 10, 2020	SELL	$57.43 - $63.64 $17,229 - $19,092	-300 Reduced 53.48%	261 $16,000
Q2 2020 Aug 10, 2020	BUY	$54.82 - $64.09 $13,705 - $16,022	250 Added 80.39%	561 $33,000
Q1 2019 May 10, 2019	SELL	$45.12 - $53.8 $292,828 - $349,162	-6,490 Reduced 95.43%	311 $15,000
Q4 2018 Feb 13, 2019	BUY	$48.76 - $63.23 $316,501 - $410,425	6,491 Added 2093.87%	6,801 $353,000
Q2 2018 Aug 08, 2018	SELL	$50.53 - $62.98 $27,185 - $33,883	-538 Reduced 63.44%	310 $17,000
Q1 2018 May 14, 2018	BUY	$59.92 - $68.98 $4,374 - $5,035	73 Added 9.42%	848 $54,000
Q4 2017 Jan 30, 2018	BUY	$59.94 - $65.35 $24,875 - $27,120	415 Added 115.28%	775 $47,000
Q3 2017 Nov 08, 2017	BUY	$55.23 - $63.74 $19,882 - $22,946	360	360 $23,000

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Roble, Belko & Company, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Roble, Belko & Company, Inc with notifications on news.

Account

Roble, Belko & Company, Inc Bristol Myers Squibb CO Transaction History